Successful treatment of a recurrent choroid plexus carcinoma with surgery followed by high-dose chemotherapy and stem cell rescue.

Abstract

Choroid plexus carcinoma (CPC) is a rare central nervous system malignant tumor with a dismal prognosis, especially in the case of incomplete resection or recurrence. The authors report long-term survival of a 1-year-old patient with recurrent CPC and Li-Fraumeni syndrome with surgical resection and high-dose chemotherapy (HDC) consisting of single cycle of Busulfan and Thiotepa followed by autologous stem cell rescue without the use of radiation therapy. Remarkably the patient remains without evidence of recurrence 5 years after completion of therapy. Additional studies are necessary to determine the role of HDC and stem cell rescue in patients with recurrent CPC.

• Authors: Othman Mosleh, Uri Tabori, Ute Bartels, Annie Huang, Tal Schechter, Eric Bouffet
• Journal: Pediatric hematology and oncology (Pediatr Hematol Oncol) Vol. 30 Issue 5 Pg. 386-91 (Aug 2013) ISSN: 1521-0669 [Electronic] England
• PMID: 23301664 (Publication Type: Case Reports, Journal Article)

Chemical References

• Thiotepa
• Busulfan

Topics

• Antineoplastic Combined Chemotherapy Protocols (therapeutic use)
• Busulfan (administration & dosage)
• Carcinoma (pathology, surgery, therapy)
• Choroid Plexus Neoplasms (pathology, surgery, therapy)
• Combined Modality Therapy
• Dose-Response Relationship, Drug
• Female
• Hematopoietic Stem Cell Transplantation
• Humans
• Infant
• Li-Fraumeni Syndrome (pathology, surgery, therapy)
• Magnetic Resonance Imaging
• Neoplasm Recurrence, Local (pathology, surgery, therapy)
• Remission Induction
• Thiotepa (administration & dosage)
• Transplantation, Autologous